FeelBetter Overview
FeelBetter's AI-powered solution identifies patients who are at high risk of near-term hospitalization related to polypharmacy issues, recommends changes to medication regimens and other needed clinical interventions, and comprehensively monitors progress at the individual and population health levels.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
FeelBetter raises $5.9M for AI-enabled medication management platform
FeelBetter, a machine learning-enabled medication-management platform, has secured $5.9 million in funding led by Firstime Ventures and Shoni Health Ventures. Other participants in the round included Random Forest VC, The Group Ventures, and existing investor Triventures. The company, which focuses on the polypharmacy paradigm, will use the funds to expand its reach and advance its platform. The latest round brings the companys total raise to $8 million.
InvestmentExpand
FeelBetter Joins Lightbeam's Marketplace to Drive Value-Based Care, Increasing Access to Solutions That Proactively Improve Medication Management Among Senior Patients
FeelBetter Launches Study to Evaluate Impact of Technology in Predicting Patients at Risk of Hospitalization Due to Sub-Optimal Medication Management
growth-positive
Israeli tech works to avert hospitalizations by flagging problems with clashing meds
FeelBetter, an Israeli company, has developed an artificial intelligence system to warn doctors about uncoordinated treatment regimens that could lead to hospitalization for elderly patients. The system, deployed by Leumit Healthcare Services, flags up to 70% of elderly patients who are at risk of hospitalization due to suboptimal polypharmacy. The AI tool analyzes medical records and identifies gaps in patient care. Leumit doctors have already received alerts from the tool and made changes to treatment regimens for hundreds of patients. The technology is currently being trialed at Brigham and Women’s Hospital in Boston. The system aims to improve patient care and reduce instances of hospitalization.
Customers
growth-negative
Teva's loss is Israeli pharma industry's gain
The article discusses Teva Pharmaceutical Industries Ltd. and its impact on the Israeli pharma industry. It mentions that Teva gave up most of its investments in Israel in 2012, leading to investments by other companies and venture capital funds. The article also highlights the wave of layoffs at Teva, which released experienced employees onto the market and accelerated the founding of new startups. Two prominent companies founded by former Teva employees, 89Bio and Clexio, are mentioned. 89Bio raised $60 million in its first financing round and focuses on developing a treatment for fatty liver. Clexio, founded as a cooperative venture between former Teva employees and Dexcel Pharma, develops products for pain, depression, and central nervous system diseases. The article also mentions a retraining program for Teva chemists as teachers.
InvestmentManagement ChangesLayoffsExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $7.4M |
| Last funding | $5.9M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 6 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | www.feelbetter.healthcare/ |
Locations
Herzliya, Israel
Boston, MA, USA
Photos & Videos
No files yet
